These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18171229)

  • 41. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine.
    Casado JL
    AIDS Rev; 2013; 15(3):139-45. PubMed ID: 24002197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
    Parienti JJ; Massari V; Descamps D; Vabret A; Bouvet E; Larouzé B; Verdon R
    Clin Infect Dis; 2004 May; 38(9):1311-6. PubMed ID: 15127346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
    HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use.
    Connoy A; Turner J; Núñez M
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):719-25. PubMed ID: 21128862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibrosis Progression in Paired Liver Biopsies from HIV/HCV-Coinfected Patients without Prior Treatment of Hepatitis C.
    Leite AG; Duarte MI; Mendes-Correa MC
    J Int Assoc Provid AIDS Care; 2015; 14(5):463-8. PubMed ID: 26056147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.
    Dybul M; Chun TW; Ward DJ; Hertogs K; Larder B; Fox CH; Orenstein JM; Baird BF; Li Y; Green LG; Engel D; Liu S; Mican JM; Fauci AS
    J Infect Dis; 2000 Apr; 181(4):1273-9. PubMed ID: 10836864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
    Couffignal C; Kolta S; Flamant M; Cazanave C; Haymann JP; Mentré F; Duval X; Leport C; Raffi F;
    AIDS Res Hum Retroviruses; 2020 May; 36(5):399-405. PubMed ID: 31891665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
    Llibre JM; Podzamczer D
    AIDS; 2012 Oct; 26(16):2117-8. PubMed ID: 23052355
    [No Abstract]   [Full Text] [Related]  

  • 52. NNRTIs: future prospects.
    Dellamonica P; Di Perri G; Garraffo R
    Med Mal Infect; 2012 Jul; 42(7):296-300. PubMed ID: 22727648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of NNRTIs in antiretroviral combination therapy: an introduction.
    Nelson M
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():1-2. PubMed ID: 11589821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
    Calza L; Manfredi R; Colangeli V; Tampellini L; Sebastiani T; Pocaterra D; Chiodo F
    AIDS; 2005 Jul; 19(10):1051-8. PubMed ID: 15958836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Van Welzen B; Mudrikova T; Arends J; Hoepelman A
    HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?
    Verma S; Wang CH; Govindarajan S; Kanel G; Squires K; Bonacini M
    Clin Infect Dis; 2006 Jan; 42(2):262-70. PubMed ID: 16355339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
    Cammett AM; MacGregor TR; Wruck JM; Felizarta F; Miailhes P; Mallolas J; Piliero PJ
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4147-52. PubMed ID: 19620337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
    Mehta U; Maartens G
    Lancet Infect Dis; 2007 Nov; 7(11):733-8. PubMed ID: 17961859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.